Paul Hastings Advises TD Cowen and BMO Capital Markets on Prime Medicine’s Public Offering of Common Stock

Paul Hastings LLP advised TD Cowen and BMO Capital Markets as underwriters in a public offering by Prime Medicine (Nasdaq: PRME) of 38,000,000 shares of common stock at a price of $3.30 per share. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of its common stock.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.4 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about August 1, 2025, subject to customary closing conditions.

Equity Capital Markets and Corporate Life Sciences chair Seo Salimi and partner Will Magioncalda led the Paul Hastings team, which included associate Chris Guerin.

More details can be found here.

About Paul Hastings

With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.